Abstract
Multikinase or tyrosine kinase inhibitors (TKI) are currently approved for radioiodine-refractory metastatic differentiated thyroid carcinoma patients. There are some anecdotal reports of the use of TKI inhibitors in the neoadjuvant setting in DTC (differentiated thyroid carcinoma) patients. But there is not much experience regarding the use of these agents in this setting. In this report, we describe the case of a 45-year-old man with unresectable locally infiltrative follicular thyroid carcinoma who underwent successful R0 resection following neoadjuvant therapy with Sorafenib. Sorafenib could be effective as neoadjuvant therapy in selected cases of locally advanced DTC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Haugen B, Alexander E, Bible K, Doherty G, Mandel S, Nikiforov Y, Pacini F, Randolph G, Sawka A, Schlumberger M, Schuff K, Sherman S, Sosa J, Steward D, Tuttle R, Wartofsky L (2016) 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1–133. https://doi.org/10.1089/thy.2015.0020
Nishida T, Nakao K, Hashimoto T (2000) Local control in differentiated thyroid carcinoma with extrathyroidal invasion. Am J Surg 179:86–91. https://doi.org/10.1016/s0002-9610(00)00275-0
Rosa Pelizzo M, Toniato A, Boschin I, Piotto A, Bernante P, Pagetta C, Palazzi M, Maria Guolo A, Preo P, Nibale O, Rubello D (2005) Locally advanced differentiated thyroid carcinoma: a 35-year mono-institutional experience in 280 patients. Nucl Med Commun 26:965–968. https://doi.org/10.1097/01.mnm.0000184936.75628.77
Patel K, Shaha A (2005) Locally advanced thyroid cancer. Curr Opin Otolaryngol Head Neck Surg 13:112–116. https://doi.org/10.1097/01.moo.0000156161.82671.43
Tsuboi M, Takizawa H, Aoyama M, Tangoku A (2017) Surgical treatment of locally advanced papillary thyroid carcinoma after response to lenvatinib: a case report. Int J Surg Case Rep 41:89–92. https://doi.org/10.1016/j.ijscr.2017.10.010
Danilovic D, Castro G, Roitberg F, Vanderlei F, Bonani F, Freitas R, Coura-Filho G, Camargo R, Kulcsar M, Marui S, Hoff A (2018) Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer. Arch Endocrinol Metab. https://doi.org/10.20945/2359-3997000000046
Stewart K, Strachan M, Srinivasan D, MacNeill M, Wall L, Nixon I (2019) Tyrosine kinase inhibitor therapy in locally advanced differentiated thyroid cancer: a case report. Eur Thyroid J 8:102–107. https://doi.org/10.1159/000494880
Nava C, Scheffel R, Cristo A, Ferreira C, Weber S, Zanella A, Paixão F, Migliavaca A, Guimarães J, Graudenz M, Dora J, Maia A (2019) Neoadjuvant multikinase inhibitor in patients with locally advanced unresectable thyroid carcinoma. Front Endocrinol. https://doi.org/10.3389/fendo.2019.00712
Iwasaki H, Toda S, Ito H, Nemoto D, Murayama D, Okubo Y, Hayashi H, Yokose T (2020) A case of unresectable papillary thyroid carcinoma treated with lenvatinib as neoadjuvant chemotherapy. Case Rep Endocrinol 2020:1–4. https://doi.org/10.1155/2020/6438352
Katoh H, Kajita S, Yokota M, Sengoku N, Sangai T (2020) Neoadjuvant use of lenvatinib in locally advanced papillary thyroid carcinoma involving critical vessels. Int J Endocrine Oncol. https://doi.org/10.2217/ije-2020-0014
Besic N, Auersperg M, Dremelj M, Vidergar-Kralj B, Gazic B (2013) Neoadjuvant chemotherapy in 16 patients with locally advanced papillary thyroid carcinoma. Thyroid 23:178–184. https://doi.org/10.1089/thy.2012.0194
Besic N, Auersperg M, Gazic B, Dremelj M, Zagar I (2012) Neoadjuvant chemotherapy in 29 patients with locally advanced follicular or hürthle cell thyroid carcinoma: a phase 2 study. Thyroid 22:131–137. https://doi.org/10.1089/thy.2011.0243
Ito Y, Higashiyama T, Hirokawa M, Fukushima M, Kihara M, Takamura Y, Kobayashi K, Miya A, Miyauchi A (2012) Clinical trial of weekly paclitaxel chemotherapy for papillary thyroid carcinoma with squamous cell carcinoma component. Endocr J 59:839–844. https://doi.org/10.1507/endocrj.ej12-0174
Author information
Authors and Affiliations
Contributions
Vikram Sharanappa, Anjali Mishra: literature search, figures, study design, data collection, data analysis, data interpretation, writing, revision, and editing of the manuscript. Sushobhan Pradhan, Prasanta Kimar Pradhan: revision and editing of the manuscript.
Corresponding author
Ethics declarations
Ethics Approval
This retrospective study does not involve any experiment on human participation. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed Consent
Informed written consent was obtained from the patient. This is to declare that all authors have contributed to the study. No part of the manuscript has been sent for consideration elsewhere or published in any International or National journal.
The authors clearly certify that there is no aspect of plagiarism. All the conflicts of interest have been clearly defined and the source of the grant disclosed. Due ethical permission/consent has been obtained for carrying out the study. In case of any dispute, the authors will be held fully responsible for the statement disclosed in the cover letter. The authors are also aware of the copyright rules and also declare that they will not reproduce any published text without due permission from the journal.
Conflict of Interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Sharanappa, V., Pradhan, S., Mishra, A. et al. Neoadjuvant Multikinase Inhibitor Therapy in Locally Advanced Unresectable Differentiated Thyroid Carcinoma: a Case Report. Indian J Surg (2022). https://doi.org/10.1007/s12262-022-03649-0
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12262-022-03649-0